Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 5/20 | 0.54 |
| ▸ | PDE4B known ✓ | Q07343 | 5/20 | 0.54 |
| ▸ | PDE4C known ✓ | Q08493 | 5/20 | 0.54 |
| ▸ | PDE4D known ✓ | Q08499 | 5/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 10/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987068 | 0.98 | TNF (0.55) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5941271 | 0.98 | TNF (0.55) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6251186 | 0.98 | TNF (0.55) | TNFPDE4APDE4BPDE4CPDE4D | |
| Acetic Acid SCHEMBL6324143 | 0.94 | ACHE (0.54) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL23000613 | 0.90 | TNF (0.46) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL21494486 | 0.90 | PDE4A (0.58) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL7746561 | 0.90 | PDE4A (0.58) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL21494477 | 0.90 | PDE4A (0.58) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL30568376 | 0.90 | PDE4A (0.58) | TNFPDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL30568368 | 0.90 | PDE4A (0.58) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3782983-A1 | ISOINDOLE DERIVATIVE | Tianjin Hemay Pharmaceutical Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019201255-A1 | ISOINDOLE DERIVATIVE | 天津合美医药科技有限公司 | 2019-10-24 | — | — | WO | disclosed |
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1004572-B1 | Amines as inhibitors of TNF alpha | CELGENE CORP (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1581205-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING (+)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1569599-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0800505-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5658940-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997012859-A1 | SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS | CELGENE CORPORATION (US) | 1997-04-10 | — | — | WO | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996020915-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | COX4I1, ALDH1A2, GDI2 | PDE4A 1740/4885PDE4B 1378/4885PDE4C 2317/4885 |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | COX4I1, ALDH1A2, GDI2 | PDE4A 1740/4885PDE4B 1378/4885PDE4C 2317/4885 |
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | PDE4A 1/4885PDE4B 4/4885PDE4C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.